

Division of 08/884,324

line 15, after "tgc-3'", insert  
--(SEQ ID NO:19)--.

Page 14, line 16, after "tcc-3'", insert  
--(SEQ ID NO:20)--; and

line 25, after "cac-3'", insert  
--(SEQ ID NO:21)--.

Page 15, line 14, after "cgg-3'", insert  
--(SEQ ID NO:22)--; and

line 18, after "ttg-3'", insert  
--(SEQ ID NO:23)--.

Page 16, line 12, after "tgc-3'", insert  
--(SEQ ID NO:24)--; and

line 16, after "-3'", insert  
--(SEQ ID NO:25)--.

Page 17, line 4, after "atc-3'", insert  
--(SEQ ID NO:26)--;

line 8, after "ttg-3'", insert  
--(SEQ ID NO:27)--;

line 22, after "ctc-3'", insert  
--(SEQ ID NO:28)--; and

line 26, after "ttg-3'", insert  
--(SEQ ID NO:29)--.

Page 18, line 11, after "tcc-3'", insert  
--(SEQ ID NO:30)--; and

line 20, after "tac-3'", insert

Division of 08/884,324

--(SEQ ID NO:31)--.

Page 19, line 11, change eukalyotic" to read --  
eukaryotic--;

line 25, delete "Patent Kokai No. 193,098/96",  
and insert therefor --patent application--.

Page 20, line 15, after "gta-3'", insert

--(SEQ ID NO:32)--; and

line 18, after "ttg-3'", insert

--(SEQ ID NO:33)--.

Page 21, line 5, after "-3'", insert

--(SEQ ID NO:34)--; and

line 8, after "atc-3'", insert

--(SEQ ID NO:35)--.

Page 22, line 19, change "abut" to read --about--.

Page 26, line 20, delete "or without"; and

line 21, delete "or 50 units/ml recombinant  
human interleukin 2".

Page 27, lines 17-18 from the bottom, delete "The IFN-  
γ production is enhanced in combination with concanavalin A or  
interleukin 2 as a cofactor."

#### REMARKS

The amendments to the specification are made to provide  
consistency with the specification as amended in the parent  
application.